Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-KB expression in MCF-7/5-FU cells

International Journal of Biochemistry and Cell Biology

Volumn 45, Issue 9, 2013, Pages 2036-2044

  Wang, Qing Ping ^a   Wang, Yu ^c   Wang, Xue Dong ^b   Mo, Xi Ming ^d   Gu, Juan ^b   Lu, Zhi Yong ^a   Pan, Zhao Lin ^b   Zhu, Yu Xi ^e  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer resistance protein; Multidrug resistance; NF B; P53; Survivin

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CHLORMETHINE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; SURVIVIN;

ARTICLE; BREAST ADENOCARCINOMA; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

5-FLUOROURACIL; 5-FU; BCRP; BREAST CANCER RESISTANCE PROTEIN; MDR; MITOXANTRONE; MULTIDRUG RESISTANCE; MX; NF-ΚB; P53; SURVIVIN;

ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MCF-7 CELLS; NEOPLASM PROTEINS; NF-KAPPA B P50 SUBUNIT; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84880872866     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2013.06.026     Document Type: Article

References (45)

1. Agarwal S, Sane R, Gallardo J.L., Ohlfest JR, Elmquist WF Distribution of gefitinib to the brain is limited by P-glycoprotein(ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. Journal of Pharmacology and Experimental Therapeutics 2010; 334(1):147-55.
2. Alla V, Kowtharapu BS, Engelmann D, Emmrich S., Schmitz U, Steder M, et al E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012; 11(16):3067-78.
3. Altieri DC. Validating survivin as a cancer therapeutic target. Nature Reviews Cancer 2003; 3(1):46-54. (Pubitemid 37328886)
4. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Current Opinion in Cell Biology 2006; 18(6):609-15. (Pubitemid 44692469)
5. Banerjee D, Bertino JR Myeloprotection with drug-resistance genes. Lancet Oncology 2002; 3(3):154-8.
6. Chandrika BB, Maney SK, Lekshmi S.U., Joseph J., Seervi M, KSP, et al. Bax deficiency mediated drug resistance can be reversed by endoplasmic reticulum stress induced death signaling. Biochemical Pharmacology 2010; 79(11):1589-99.
7. Chauhan PS, Bhushan B, Singh L.C., Mishra AK, Saluja S, Mittal V, et al Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy. Experimental and Molecular Pathology 2012; 92(1):44-9.
8. Chen YJ, Huang WC, Wei Y.L., Hsu SC, Yuan P, Lin HY, et al Elevated BCRP/ABCG2 expressionconfers acquired resistancetogefitinib in wild-type EGFR-expressing cells. PLoS ONE 2011; 6(6):e21428.
9. Chuthapisith S, Eremin JM, El-Sheemy M, Eremin O. Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. Surgeon 2006; 4(4):211-9. (Pubitemid 44165021)
10. Doyle LA, Ross DD Multidrug resistance mediated by the breast cancer resistance protein BCRP(ABCG2). Oncogene 2003; 22(47):7340-58. (Pubitemid 37487163)
11. Doyle LA, Yang W, Abruzzo L.V., Krogmann T., Gao Y, Rishi AK, et al A multidrug resistance transporter from human MCF-7 breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 1998; 95(26):15665-70. (Pubitemid 29018757)
12. Ee PL, Kamalakaran S, Tonetti D., He X, Ross DD, Beck WT Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Research 2004; 64(4):1247-51. (Pubitemid 38235590)
13. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003; 22(56):9030-40. (Pubitemid 38121703)
14. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. Journal of Biological Chemistry 2002; 277(5):3247-57. (Pubitemid 34953189)
15. Huang Y, Ibrado AM, Reed J.C., Bullock G., Ray S, Tang C, et al Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997; 11(2):253-7. (Pubitemid 27085170)
16. Ikeguchi M, Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. British Journal of Cancer 2002; 87(8):883-7. (Pubitemid 35252964)
17. Ji N, Yuan J, Liu J., Tian S. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase. Acta Biochimicaet BiophysicaSinica (Shanghai) 2010; 42(12):854-62.
18. Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn D.J., Orlowski RZ Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Molecular Cancer Therapeutics 2012; 11(10):2243-53.
19. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S., Mercer KE, et al The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. Journal of Biological Chemistry 2004; 279(23):24218-25. (Pubitemid 38725283)
20. Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance. Advances in Experimental Medicine and Biology 2007; 608:23-30.
21. Metzinger DS, Taylor DD, Gercel-Taylor C. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines. Cancer Letters 2006; 236(2):302-8. (Pubitemid 44262308)
22. Mirza A, McGuirk M, Hockenberry T.N., Wu Q., Ashar H, Black S, et al Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21(17):2613-22. (Pubitemid 34478319)
23. Natarajan K, Xie Y, Baer M.R., Ross DD Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochemical Pharmacology 2012; 83(8):1084-103.
24. Noordhuis P, Holwerda U, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Annals of Oncology 2004; 15(7):1025-32. (Pubitemid 39089778)
25. O'Connor D.S., Grossman D, Plescia J., Li F, Zhang H, Villa A., et al Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proceedings of the National Academy of Sciences of the United States of America 2000; 97(24):13103-7.
26. Pradhan M, Bembinster LA, Baumgarten S.C., Frasor J. Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF(kappa)B cooperativity at adjacent response elements. Journal of Biological Chemistry 2010; 285(41):31100-6.
27. Robey RW, Polgar O, Deeken J., To KW, Bates SE ABCG2: determining its relevance in clinical drug resistance. Cancer and Metastasis Reviews 2007; 26(1):39-57. (Pubitemid 46452182)
28. Rodel C, Haas J, Groth A., Grabenbauer GG, Sauer R, Rodel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. International Journal of Radiation Oncology, Biology, Physics 2003; 55(5):1341-7. (Pubitemid 36338302)
29. Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia 2000; 14(3):467-73. (Pubitemid 30142873)
30. Ryan BM, Konecny GE, Kahlert S, Wang H.J., Untch M., Meng G, et al Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Annals of Oncology 2006; 17(4):597-604.
31. Schinkel AH, Jonker JW Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Advanced Drug Delivery Reviews 2003; 55(1):3-29. (Pubitemid 36078452)
32. Singh RR, Kunkalla K, Qu C., Schlette E, Neelapu SS, Samaniego F, et al ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 2011; 30(49):4874-86.
33. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. Journal of Biological Chemistry 2003; 278(25):23130-40. (Pubitemid 36830379)
34. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000; 65(1):95-106.
35. Swana HS, Grossman D, Anthony J.N., Weiss RM, Altieri DC Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. New England Journal of Medicine 1999; 341(6):452-3. (Pubitemid 29362524)
36. Tran J, Master Z, Yu J.L., Rak J., Dumont DJ, Kerbel RS A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proceedings of the National Academy of Sciences of the United States of America 2002; 99(7):4349-54. (Pubitemid 34285988)
37. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nature Reviews Cancer 2002; 2(8):594-604. (Pubitemid 37328926)
38. Wang X, Wu X, Wang C., Zhang W, Ouyang Y, Yu Y., et al Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-kappaB pathway in MCF-7 cells. FEBS Letters 2010; 584(15):3392-7.
39. Wang Z, Fukuda S, Pelus LM Survivin regulates the p53 tumor suppressor gene family. Oncogene 2004; 23(49):8146-53. (Pubitemid 39531855)
40. Wesarg E, Hoffarth S, Wiewrodt R., Kroll M, Biesterfeld S, Huber C., et al Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. International Journal of Cancer 2007; 121(11):2387-94. (Pubitemid 350022407)
41. Yu M, Ocana A, Tannock IF Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer and Metastasis Reviews 2013; 32(1-2):211-27.
42. Yuan J, Lv H, Peng B., Wang C, Yu Y, He Z. Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemotherapy and Pharmacology 2009; 63(6):1103-10.
43. Zhang M, Latham DE, Delaney M.A., Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005; 24(15):2474-82. (Pubitemid 40593038)
44. Zheng G, Peng F, Ding R., Yu Y, Ouyang Y, Chen Z., et al Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil- induced breast cancer cell using proteomics analysis. Journal of Cancer Research and Clinical Oncology 2010; 136(10):1477-88.
45. Zheng WE, Chen H, Yuan S.F., Wu LL, Zhang W, Sun HY, et al Overexpression of betaIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer. Journal of BUON 2012; 17(2):284-90.